Citigroup Inc. reaffirmed their buy rating on shares of Allergan PLC. (NYSE:AGN) in a report published on Wednesday. They currently have a $280.00 target price on the stock.

Several other equities research analysts have also recently issued reports on the stock. UBS AG reissued an outperform rating and issued a $275.00 target price on shares of Allergan PLC. in a research report on Wednesday, August 9th. BidaskClub cut shares of Allergan PLC. from a buy rating to a hold rating in a research report on Wednesday, August 9th. Wells Fargo & Company reissued an outperform rating and issued a $280.00 target price (up from $270.00) on shares of Allergan PLC. in a research report on Wednesday, August 9th. Cantor Fitzgerald reissued a hold rating on shares of Allergan PLC. in a research report on Tuesday, August 22nd. Finally, Argus reissued a buy rating and issued a $280.00 target price on shares of Allergan PLC. in a research report on Monday, August 14th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and fourteen have assigned a buy rating to the stock. The company currently has a consensus rating of Buy and a consensus target price of $273.34.

Allergan PLC. (AGN) opened at 204.65 on Wednesday. Allergan PLC. has a 52-week low of $184.50 and a 52-week high of $256.80. The firm has a market capitalization of $68.42 billion, a price-to-earnings ratio of 6.24 and a beta of 1.18. The company’s 50-day moving average is $229.79 and its 200-day moving average is $236.07.

Allergan PLC. (NYSE:AGN) last issued its quarterly earnings results on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, topping analysts’ consensus estimates of $3.95 by $0.07. The business had revenue of $4.01 billion during the quarter, compared to the consensus estimate of $3.95 billion. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The company’s quarterly revenue was up 8.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.35 earnings per share. Equities analysts predict that Allergan PLC. will post $16.26 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Allergan PLC. (AGN) Given “Buy” Rating at Citigroup Inc.” was reported by Daily Political and is the property of of Daily Political. If you are reading this story on another website, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/09/24/allergan-plc-agn-given-buy-rating-at-citigroup-inc.html.

The business also recently declared a quarterly dividend, which was paid on Friday, September 15th. Investors of record on Friday, August 18th were paid a $0.70 dividend. The ex-dividend date of this dividend was Wednesday, August 16th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.37%. Allergan PLC.’s dividend payout ratio (DPR) is presently 9.95%.

Several large investors have recently modified their holdings of AGN. Veritas Asset Management LLP bought a new stake in shares of Allergan PLC. in the first quarter worth $761,339,000. Iridian Asset Management LLC CT increased its stake in Allergan PLC. by 141.3% during the first quarter. Iridian Asset Management LLC CT now owns 1,283,833 shares of the company’s stock valued at $306,733,000 after purchasing an additional 751,848 shares during the last quarter. Renaissance Technologies LLC bought a new stake in Allergan PLC. during the first quarter valued at $124,255,000. Vanguard Group Inc. increased its stake in Allergan PLC. by 2.2% during the second quarter. Vanguard Group Inc. now owns 22,835,689 shares of the company’s stock valued at $5,551,128,000 after purchasing an additional 482,220 shares during the last quarter. Finally, Blue Ridge Capital L.L.C. increased its stake in Allergan PLC. by 24.1% during the first quarter. Blue Ridge Capital L.L.C. now owns 1,909,900 shares of the company’s stock valued at $456,313,000 after purchasing an additional 370,400 shares during the last quarter. Institutional investors and hedge funds own 82.02% of the company’s stock.

About Allergan PLC.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Analyst Recommendations for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.